Which is the better dividend stock: Royal Dutch Shell plc or GlaxoSmithKline plc?

Royal Dutch Shell plc (LON: RDSB) and GlaxoSmithKline plc (LON: GSK) are two of the most popular dividend stocks, but does one have stronger dividend prospects?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Royal Dutch Shell (LSE: RDSB) and GlaxoSmithKline (LSE: GSK) are two of the most popular dividend stocks in the FTSE 100 index. I own both in my own portfolio. However, neither Shell nor Glaxo are perfect dividend stocks, in my view. Both have struggled with profitability in recent years, and as a result, have not increased their payouts. Today, I’m comparing the two companies. Is one a better dividend stock than the other?

Dividend yield

Beginning the analysis by looking at each company’s yield reveals that GlaxoSmithKline has a higher dividend yield than Shell right now. Shell paid its shareholders $1.88 in dividends last year, a yield of 5.9% at the current share price and exchange rate. Glaxo paid investors 80p per share, a yield of 6.2%. The healthcare giant wins here.

Recent dividend growth

Examining recent dividend growth, between 2014 and 2016, Shell paid shareholders $1.88, $1.88 and $1.88. No growth was recorded, however, with the pound having fallen against the dollar, UK investors will have enjoyed a rise in the yield. In comparison, Glaxo, which declares its payout in GBP, paid 80p, 80p and 80p in that time. Again, no growth. However, the company did pay a special dividend of 20p per share in 2015. On that basis, I’ll give Glaxo the win in this department too. 

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Dividend cover

City analysts expect Shell to generate earnings per share of $2 this year. That gives a dividend coverage ratio of just 1.06 times last year’s payout. In comparison, analysts expect Glaxo’s earnings to come in at 111p. That gives a coverage ratio of 1.39 times last year’s payout. Glaxo has the upper hand here, although neither ratio is strong. 

Valuation

GlaxoSmithKline shares are also cheaper than Shell shares right now. The healthcare specialist sports a forward looking P/E ratio of just 11.8, vs 15.9 for Shell.

So far, Glaxo looks to be the better dividend stock. However, I’m not entirely convinced that it is.

Dividend outlook

The reason I say this is that Shell appears to have momentum at the moment. The oil price is back up to around $60 per barrel, and at that price, Shell can generate decent levels of free cash flow. With the merger of BG Group complete, Shell’s dividend is looking more and more sustainable, assuming the oil price doesn’t crash again. The stock’s 10% gain over the last three months reflects this.

In contrast, I’m getting more concerned about the sustainability of Glaxo’s dividend. Free cash flow is low, and with the group looking at potential acquisitions such as that of Pfizer, there could be implications for the payout.

When asked recently whether such a deal would carry dividend risk, CEO Emma Walmsley replied: “We confirmed our intentions to pay the dividend in 2017 of 80 pence and again in 2018 and then we will be returning to declaring the dividend quarterly and not giving a more specific outlook beyond that.”

Lack of long-term dividend assurance has rattled investors, with the stock falling 15% over the last three months. The market clearly has doubts about the sustainability of GlaxoSmithKline’s dividend.

So while Glaxo has the lower valuation, higher yield and better coverage, if I was to pick one dividend stock between the two right now, I’d be inclined to go with Shell. I believe there’s less chance of a dividend cut with Shell, assuming the oil price doesn’t plummet again. 

However, don’t buy any shares just yet

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Secure your FREE copy

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon owns shares in Royal Dutch Shell and GlaxoSmithKline. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Royal Dutch Shell B. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

We think earning passive income has never been easier

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 in savings? Here’s how it could be used to target a £913 second income each month

Christopher Ruane walks through some practicalities of how an idle £20k could be the foundation for a sizeable long-term second…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

5 steps to building monthly passive income with a spare £10k

Christopher explains how an investor could aim to use some spare cash to start building regular passive income streams through…

Read more »

Blue NIO sports car in Oslo showroom
Investing Articles

Tesla’s struggling. Could NIO stock benefit?

NIO stock has moved up very slightly this year, while Tesla has crashed. Our writer considers whether it might be…

Read more »

Two employees sat at desk welcoming customer to a Tesla car showroom
Investing Articles

Could Tesla stock be a brilliant bargain in plain sight?

Christopher Ruane sees some things to like about Tesla, but as its vehicle revenues have gone into sharp decline, is…

Read more »

British coins and bank notes scattered on a surface
Investing Articles

3 cheap FTSE 250 stocks with big dividends to consider buying right now

The FTSE 250's loaded with so many big dividend yields it's hard to know where to start. These three have…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Up 585%, could Rolls-Royce shares still go higher?

Christopher Ruane likes the Rolls-Royce business but is not so convinced by the value its current share price offers him.…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

I reckon a bull market’s coming! Here’s what I’m buying for my Stocks and Shares ISA

Hoping to capitalise on what he believes is an undervalued UK stock market, our writer’s added more of this FTSE…

Read more »

piggy bank, searching with binoculars
Investing Articles

The UK stock market looks undervalued to me. Here’s 1 growth stock to consider for a SIPP

Our writer explains why he thinks the UK stock market’s currently in bargain territory, and identifies one share potentially worthy…

Read more »